# Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

> **NCT05176925** · PHASE2 · TERMINATED · sponsor: **Fudan University** · enrollment: 5 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Sitravatinib

## Key facts

- **NCT ID:** NCT05176925
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-10
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-09-28
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The trial was terminated per sponsor recommendation
- **Last updated:** 2024-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176925, "Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05176925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*